TWD 70.0
(-4.11%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 126.67 Million TWD | 24.51% |
2022 | 101.74 Million TWD | 29.93% |
2021 | 78.3 Million TWD | -13.1% |
2020 | 90.1 Million TWD | -0.99% |
2019 | 91 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 33.8 Million TWD | 5.98% |
2024 Q1 | 31.9 Million TWD | 11.72% |
2023 Q4 | 28.55 Million TWD | -4.15% |
2023 FY | - TWD | 24.51% |
2023 Q3 | 29.79 Million TWD | -14.46% |
2023 Q1 | 33.5 Million TWD | 18.07% |
2023 Q2 | 34.83 Million TWD | 3.97% |
2022 FY | - TWD | 29.93% |
2022 Q4 | 28.37 Million TWD | 0.0% |
2021 FY | - TWD | -13.1% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | 38.143% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 45.183% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 248.16% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 91.69% |
Synmosa Biopharma Corporation | 1 Billion TWD | 87.442% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 78.269% |
Center Laboratories, Inc. | -175.17 Million TWD | 172.317% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -308.007% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | 26.519% |
InnoPharmax Inc. | -62.12 Million TWD | 303.925% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 531.332% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 68.924% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 113.888% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 84.22% |
UniPharma Co., Ltd. | -16.25 Million TWD | 879.365% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 3.528% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 67.891% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 44.519% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 424.532% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -943.906% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -27.507% |